Condition
Hip Avascular Necrosis: Options and What the Evidence Actually Shows
Early-stage AVN is one of the cleanest mechanistic cases in regenerative orthopedics — and still a specialist decision.
Anatomy and clinical context
AVN is bone death in the femoral head from disrupted blood supply. Collapse converts a joint-preserving problem into an arthroplasty problem.
Staging (e.g. ARCO) drives whether core decompression ± adjuncts are reasonable versus proceeding to replacement.
Illustration of the hip joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Protected weight bearing and risk-factor management in very early disease.
- Step 2
Injections
Core decompression ± bone graft or orthobiologic adjuncts in selected pre-collapse stages.
- Step 3
Surgery
Total hip arthroplasty after collapse or failed joint-preserving care.
Where cell therapy fits
AVN attracts regenerative interest because biology and timing matter. Evidence quality varies; choose centers that stage honestly.
- Pre-collapse vs post-collapse changes everything.
- Cell adjuncts are not magic — they are tools inside staged care.
- Banking younger cells may matter if expanded autologous products become part of future protocols.
Selected citations
Stempeucel
Approved product (India) · Regulatory approval (2020)
Culture-expanded MSC product approved in India — example of dose-enabled products showing clinical pathway beyond same-day unexpanded injectates.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.